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R780system, where non-sexualised 
images, e.g. from clothes ads or even 
from nudist beaches get the green 
light, erotic posing counts as amber, 
and material focusing on genitals 
or actual acts of child abuse gets 
the red light. “We train the patient 
to move only in the green area,” 
Ahlers told the paper. “Amber means: 
Caution! Potential danger for children 
and for myself! Risky behaviour on 
the verge of problematic behaviour!”
There is an interesting philosophical 
dilemma here, considering one 
observation reported in Bering’s book 
that sexual abuse of children appears 
to have diminished in places where 
child pornography was briefly legally 
available. The case for punishing 
people found with such material 
on their computers is, of course, 
that children are harmed during the 
production of the images, often with 
the financial support of the end-user. 
If, however, the known paedophiles 
who have sought professional help 
were to be given computer-animated 
material, which was produced without 
harming any children at all, should 
that still be illegal? Even child-like 
robots have recently been proposed 
as a therapy help for paedophiles. 
Hard scientific data would be needed 
to establish whether any such tool can 
in fact contribute to child protection. 
The current demonisation of people 
with this particular orientation makes 
it practically impossible to get 
this kind of data. Even under less 
hostile conditions, all research and 
treatment attempts will rely on those 
individuals willing to participate. 
There may be a hard core who 
would remain inaccessible under any 
circumstances. 
In the UK, recent changes to the 
law championed by the mass-market 
newspapers served to ostracise 
paedophiles even further and 
make their resocialisation virtually 
impossible. Changes in the opposite 
direction would be needed and, given 
the current media frenzy, that would 
be a suicide mission unlikely to be 
undertaken by any government. The 
road to a rational, evidence-based 
policy offering people with paraphilias 
help instead of blanket condemnation 
based on a presumption of guilt will 
be a long one. 
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Your career has ranged from basic 
biochemistry and cell biology to 
physiology and drug development. 
How did you get involved in these 
diverse areas and which has been 
most fun? I’ve been fortunate in 
being able both to contribute to basic 
knowledge about protein breakdown 
and to work as part of a team that 
translated this knowledge into 
medicines (proteasome inhibitors) 
that have helped many patients. 
Both types of research can be 
enormously rewarding. Which is 
most satisfying to do is a matter of 
personal taste. However, because 
medical applications are so dependent 
on basic understanding, the more a 
scientist knows about fundamental 
Q & A mechanisms, the better equipped he or she is to pursue drug development. 
The primary reason that I’ve been 
able to contribute to these multiple 
areas is my mixed background and 
strong interests in both the functioning 
of organisms and molecular 
mechanisms. My career path was 
rather haphazard, and not one I’d 
recommend to a young scientist today, 
now that so much professionalism is 
required to do serious research. I know 
a lot about mammals and disease, 
because I had studied physiology 
as a Churchill Scholar in Cambridge 
University and then for two years was 
a medical student at Harvard, until 
I realized that medical school was 
interfering with my education. I then 
decided to go on a leave of absence 
to pursue in depth some research that 
I was involved in. In fact, for almost 
50 years, I have officially been a 
Harvard medical student ‘on leave of 
absence’. In the interim, I received a 
PhD, joined the faculty, and grew old 
in the same building where I started 
medical school in 1964. However, this 
background was certainly valuable 
and exposed me to many phenomena 
I built on or investigated in later years. 
In fact, I strongly recommend a serious 
exposure to human physiology and 
disease for all PhD students because 
of its professional utility and its 
inherent interest. 
I was also motivated and able 
to explore molecular mechanisms 
because I had been smitten by the 
excitement of molecular biology when I 
was an undergraduate at Harvard, and 
some special opportunities opened 
up for me. After my second year, I 
was chosen for a summer program to 
introduce undergraduates to research 
at Cold Spring Harbor Laboratories 
where the excitement of discovery 
was infectious. Also, to graduate with 
honors, one had to do a research 
thesis, and I was fortunate to do mine 
in the laboratory of Jim Watson, then a 
Professor at Harvard. The opportunity 
to interact with some of the greats of 
molecular biology was truly seductive. 
Watson received the Nobel Prize my 
first summer in his lab, which was 
full of very talented people (e.g. two 
members, Mario Capecchi and Wally 
Gilbert, were future Nobel laureates). 
The most important lesson I learned 
there was not from my research 
on Escherichia coli ribosomes or 
publishing my findings, but was from 
Jim and Wally about the importance of 
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to work on and to have the courage to 
pursue it.
There must be real satisfaction 
in looking back over 45 years and 
seeing how knowledge about 
protein degradation developed so 
dramatically. It’s been wonderful to be 
able to play a major role in this field’s 
development — from a topic that few 
people thought worthy of study to 
one which is central to understanding 
many aspects of cell function. When 
I started my lab in 1969, almost 
nothing was known about why cells 
degraded proteins, or how this process 
occurred. I therefore had the freedom 
to investigate all these basic questions, 
which led unexpectedly to new types 
of enzymes (ATP-dependent proteases 
and proteasomes). Because few were 
interested in the field, we did not worry 
about labs competing with us. That 
luxury has long disappeared. Now we 
suffer from the opposite challenge of 
keeping up with the explosion of new 
discoveries.
It is hard now to appreciate how 
much freedom this degree of ignorance 
provided. Because my findings as a 
student had convinced me that protein 
breakdown was a fundamentally 
important feature of cells, in 
establishing my own lab I decided 
to focus on this area. I continued to 
study the regulation of protein turnover 
in muscle, because I had found that 
atrophy occurred primarily through 
an acceleration of proteolysis, and 
this process was of medical interest. 
However, I especially wanted to learn 
why cells degraded proteins at all, 
since this process seemed highly 
wasteful. Therefore, I chose to pursue 
such questions in E. coli, because they 
provided enormous advantages for 
genetic and biochemical studies. (Also, 
I enjoyed both growing bacteria and 
operating on rodents.)
Studying protein degradation in 
E. coli sounds like a strange choice, 
especially since you were an 
Assistant Professor of mammalian 
physiology. Certainly, and even I 
realized that E. coli was not a mammal! 
Thankfully, my colleagues viewed 
physiology in its broadest sense and, 
though my grants concerned muscle, 
the NIH recognized that, in using E. coli, 
we were asking questions about the 
functioning of all cells. Nowadays, few 
departments or granting agencies are so enlightened. However, it was also 
considered a foolish choice by my 
biochemistry friends because Jacques 
Monod, one of my scientific heroes, 
had published that protein breakdown 
did not occur in growing bacteria and 
argued that the reports that proteins 
in mammalian cells were continually 
turning over were artifactual. However, 
we and others demonstrated in 
the early 70s that bacteria, during 
exponential growth, degraded rapidly 
misfolded or mutated proteins, as we 
also showed in rabbit reticulocytes and 
even mitochondria. 
In fact, we were the first group to 
emphasize the importance of protein 
degradation in cellular quality control 
and homeostasis. At the time, this 
fundamental role for protein turnover 
was not widely recognized. Probably 
my most influential early publication 
was a lengthy two-part review in the 
Annual Review of Biochemistry (1974). 
In those pre-internet days, preparing 
reviews was an act of martyrdom, 
requiring weeks in libraries, but was 
crucial in providing guides to the 
literature. However, my goal was 
different — to influence thinking and 
spread the gospel that a protein’s 
stability in cells was determined by its 
structure, i.e. its primary sequence, 
proper folding, and ligand binding. 
The major message in the second 
part of the review (published in 1976) 
was also noteworthy — that protein 
breakdown was so selective that it 
could not be due to lysosomes, as 
believed. So there had to exist a non-
lysosomal process that required ATP 
and selectively removed abnormal and 
regulatory proteins, as we showed the 
subsequent year in reticulocytes and 
bacteria. Since then, the elucidation of 
these systems and their unexpectedly 
complex mechanisms has kept a large 
number of investigators quite busy.
But isn’t protein breakdown a very 
different process in bacteria and 
eukaryotes? Yes, but we didn’t know 
that in 1969. In choosing to study 
E. coli, I was building on the widespread 
belief at the time, that if we understood 
E. coli, we would understand the 
elephant. This was certainly naive in the 
case of protein breakdown. Although 
protein breakdown serves similar 
functions in eukaryotes as in E. coli, 
these bacterial cells lack ubiquitin 
and proteasomes. In fact, our focus 
on bacteria probably explains our 
failure to discover the role of ubiquitin in our reticulocyte system, which was 
the seminal contribution of Hershko, 
Ciechanover and Rose (for which they 
received the Nobel prize in 2005).
So, was studying bacteria a mistake 
or a distraction? Definitely not. 
These cells allowed us to clarify 
the physiological roles of protein 
breakdown and in subsequent 
mechanistic studies, we discovered 
ATP-hydrolyzing proteases (Lon, 
Clp, HslUV). Also knowledge gained 
about these novel multimeric enzymes 
enabled us and Rechsteiner’s group 
to demonstrate the eukaryotic 26S 
proteasome, which catalyzes the 
ATP-dependent degradation of 
ubiquitinated proteins and shares 
mechanistic features with these 
bacterial enzymes. 
In addition, to our surprise, these 
basic discoveries in E. coli proved 
to be of practical importance. With 
the development of the recombinant 
DNA industry, knowledge about 
protein breakdown in E. coli became 
of considerable industrial relevance. 
A major unanticipated barrier to the 
expression of many proteins of medical 
interest (e.g. insulin) was that the 
E. coli rapidly degraded the foreign 
protein. Thus, knowledge we had 
gained about the enzymes that digest 
misfolded proteins, about mutants 
defective in this process, or about 
the tendency of misfolded proteins 
to form easily-isolated intracellular 
inclusions influenced the development 
of industrial procedures. Suddenly, the 
importance of protein degradation in 
bacteria became widely appreciated, 
and our phones started ringing 
frequently as company scientists 
sought advice. This is a great example 
of the unpredictable benefits of basic 
research. 
How did you first become interested 
in this neglected area? This interest in 
protein degradation arose accidentally 
through experiments I did as a student 
on muscle atrophy. In my anatomy 
course, we were supposed to know 
if a specific nerve was cut, what 
muscles became inactive and therefore 
atrophied. I started wondering how an 
inactive muscle actually decreased 
in protein content. Because the 
literature provided no insights, I 
initiated experiments which I assumed 
would indicate how inactivity reduced 
protein synthesis. Surprisingly, I 
found that synthesis in the atrophying 
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and therefore I began thinking about 
protein breakdown. Eventually by 
using an abundance of rats and 
radioactive amino acids (which in 
those days students could use without 
restrictions), I showed that disuse and 
fasting decreased muscle size mainly 
by accelerating protein breakdown. 
The realization that organ size was 
determined by an unknown process 
was exciting and more interesting 
to pursue than completing medical 
school. Because I knew the advantages 
of bacteria and reticulocytes for 
understanding protein synthesis, the 
path forward seemed clear. 
In truth, these career decisions 
were more difficult than this account 
implies. My ability to follow my own 
curiosity was only possible through the 
encouragement and support of certain 
great figures on the Harvard faculty 
— especially my extremely generous 
mentor Moe Goodman, but also David 
Hubel, Torsten Wiesel, Gene Kennedy, 
Arthur Pardee, Bernie Davis and Alex 
Rich (MIT), who were both thoughtful 
sources of advice and role models.
These interests seem far removed 
from starting a biotech company 
and developing drugs against blood 
cancers. If one works on fundamental 
cellular processes, one can not 
always predict where it may lead you. 
Although I’m supposed to be rather 
knowledgeable about physiology and 
disease, in developing proteasome 
inhibitors we never foresaw that 
they would be used to treat multiple 
myeloma, the cancer of plasma cells. 
Our drug-development efforts, which 
I described elsewhere (J. Cell Biol. 
(2012) 199, 584–588), emerged from 
our discovery in the late 1980s that the 
ubiquitin–proteasome pathway not only 
eliminates misfolded and regulatory 
proteins, but also catalyzes the slower 
breakdown of most cellular proteins. 
Specifically, we found that this pathway 
was activated during muscle wasting 
(e.g. in cancer cachexia) through a 
specific transcriptional program, and 
its activation is the primary cause of 
the atrophy. This recognition led to 
my original rationale for wanting to 
make proteasome inhibitors — the 
naive hope that, by partially inhibiting 
proteasome function, we could reduce 
this debilitating excessive proteolysis. 
Also, by 1992, we knew enough 
about the proteasome’s mechanism 
to see a rational approach for inhibitor synthesis. I decided to found a biotech 
company because there was no 
mechanism within the university to 
bring together a team with the multiple 
types of expertise needed to develop 
a drug. Also, in advising biotech 
companies, I had found that working 
with a talented team on a common goal 
could be stimulating and fun. I was 
able to convince several colleagues 
and a venture capitalist to help found 
a small company with the initial goal of 
combatting muscle wasting, but I also 
had a hidden agenda. I realized that 
proteasome inhibitors that were active 
in cells would be very valuable tools 
to clarify the physiological functions 
of the proteasome. In fact, our early 
inhibitor, MG 132, has now been used in 
thousands of publications and enabled 
the elucidation of many key cellular 
processes. 
Amongst the important functions 
discovered was the proteasome’s role 
in activating the transcription factor 
NFκB. Because of the critical role of 
NFκB in inflammation and growth of 
many cancers, the company changed 
its focus. Chemists in the company 
soon generated the peptide boronate, 
bortezomib/Velcade, which was 
active in several disease models and 
eventually entered trials against all 
cancers. Dramatic responses were 
seen in patients with multiple myeloma. 
Consequently, this agent gained rapid 
FDA approval in 2004 and has already 
helped prolong the lives of several 
hundred thousand patients. The 
special sensitivity of myeloma cells to 
proteasome inhibition was not foreseen 
and became clear only in clinical trials. 
This unique sensitivity is a result of 
these cells being exceptionally active 
in degrading misfolded proteins 
(abnormal immunoglobulins) and highly 
dependent on NFκB. 
Bortezomib’s development is further 
evidence that medical and scientific 
advances go hand in hand, and that 
the benefits of basic discoveries are 
often not predictable. Unfortunately, 
granting agencies in their zeal to assist 
patients, often forget these truths.
You have been doing biomedical 
research for 50 years now. How 
different is it to do science now 
compared with back then? 
Enormously. Back in the 70s and 80s, 
we spent a lot less time preparing 
research grants, worrying about job 
prospects, or arguing with referees. 
Nevertheless, people worked very hard. Also, because so little was 
known, even students were at the 
frontiers of knowledge. Unfortunately, 
the enormous amount of information 
that has accumulated since then 
seems to intimidate young people 
from asking fundamental questions 
or speculating about new areas. 
Perhaps because I grew up in those 
Dark Ages, I’ve never been afraid to 
ask naïve questions or delve into new 
areas. In fact, by bringing an outsider’s 
perspective, I have been able to 
contribute to areas where I lacked 
professional credentials (e.g. antigen 
presentation). Consequently, I believe 
some naiveté together with curiosity 
(and chutzpah) are valuable assets for 
a scientist.
Certainly, doing research today is 
more fast-paced and technically easier. 
Before the 1990s, getting answers 
to biochemical questions was much 
harder because virtually all the methods 
we now use were not available or 
even imaginable. If someone had told 
me in 1985 that we could test our 
speculations by repressing a specific 
mRNA in cells or by downloading in 
seconds to a pocket telephone the 
structure of a protein from some mega-
library in the sky, I would have thought it 
an amusing science-fiction plot. These 
tools are enormously empowering and 
have allowed us to replace ignorance 
with knowledge. Unfortunately, younger 
investigators take these advances for 
granted and often miss the great beauty 
of the achievements that we continually 
build on. Few papers cite work more 
than a few years old, and while it’s 
appropriate that scientists focus on 
what’s new and exciting, in doing so, 
we often forget where ideas come from 
and lose a sense of continuity and our 
work’s larger context.
You’re starting to sound geriatric. 
Soon you’ll be reminiscing in your 
rocking chair about the Good 
Old Days… perhaps even voting 
Republican? I certainly hope not! 
I’m still running a very active lab and 
am still excited by new findings. This 
continued stimulation exceeds that 
of anything else I can imagine doing. 
Otherwise, I would have retired years 
ago and spent my time writing pieces 
like this one.
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